Table 4

Definition of MCII with ESSDAI and ESSPRI

EULAR cohortASSESS cohort
Baseline—6 monthsBaseline—1 year
ESSDAI MCII [95% CI]
In the whole cohortN=47N=49
 Absolute change−4 [−5 to −2]−1 [−3 to 0]
 Relative change (% of baseline value)−52.8% [80.0 to 9.1]−14.9% [−57.1 to 0.0]
Among patients with ESSDAI≥5 at baselineN=37N=18
 Absolute change−5 [−7 to −2]−3 [−5 to 0]
 Relative change (% of baseline value)−60.1% [83.3 to 22.2]−27.1% [−66.7 to 0.0]
ESSPRI MCII [95% CI]
In the whole cohort
 Improved patients according to Likert scaleN=87NA
  Absolute change−0.67 [−1.00 to −0.33]
  Relative change (% of baseline value)−11.1% [−18.8 to −5.0]
 Improved patients according to binary questionN=69
  Absolute change−0.67 [−1.00 to 0.00]
  Relative change (% of baseline value)−10.7% [−18.7 to −4.5]
Among patients with ESSPRI≥5 at baseline
 Improved patients according to Likert scaleN=49NA
  Absolute change−1.00 [−1.33 to −0.67]
  Relative change (% of baseline value)−16.6% [−21.7 to −10.5]
 Improved patients according to binary questionN=50
  Absolute change−1.00 [−1.33 to −0.67]
  Relative change (% of baseline value)−15.6% [−23.1 to −10.0]
  • ASSESS, Assessment of Systemic Signs and Evolution of SS; EULAR, European League Against Rheumatism; ESSDAI, EULAR Sjögren's syndrome disease activity index; ESSPRI, EULAR Sjögren's syndrome patient-reported index; MCII, minimal clinically important improvement; NA, not available.